首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1475197

全球慢性腎臟病 (CKD) 藥物市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢和預測

Global Chronic Kidney Disease (CKD) Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年04月01日 | 出版商:

Value Market Research | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球慢性腎臟病 (CKD) 藥物市場需求預計將從 2023 年的 150.6 億美元達到近 236.9 億美元的市場規模，2024-2032 年研究期間複合年成長率為 5.16%。

慢性腎臟病 (CKD) 藥物是用於治療和管理長期腎臟損傷和功能障礙的藥劑。他們的目標是減緩腎臟疾病的進展，控制症狀，管理併發症，並降低與腎功能受損有關的心血管事件和死亡的風險。這些藥物可能包括血管張力素轉換酶 (ACE) 抑制劑、血管張力素 II 受體阻斷劑 (ARB)、利尿劑、紅血球生成促效劑 (ESA)、磷酸鹽結合劑和維生素 D 類似物等。

市場動態

糖尿病、高血壓、肥胖和人口老化等危險因子的持續發生，推動了 CKD 的盛行率，導致越來越多的患者群體需要藥物干預來減緩疾病進展、控制症狀和提高生活品質。隨著人們對CKD 認知的不斷提高、早期檢測舉措以及推動識別高風險個體和無症狀病例的篩檢計劃的實施等因素，對具有腎臟保護作用、降低心血管風險和預防疾病的CKD 藥物的需求不斷成長。

此外，隨著製藥公司、生物技術新創公司和學術研究人員投資於針對 CKD 併發症的藥物發現和開發項目，人們越來越認知到 CKD 作為全球公共衛生挑戰，推動了市場創新。此外，隨著製造商探索監管途徑、展示臨床療效並獲得市場批准，不斷變化的監管環境、臨床試驗設計和報銷政策推動了 CKD 藥物的市場競爭、定價動態和市場准入。然而，對藥物安全性、有效性和不良反應的擔憂可能會挑戰未來幾年慢性腎臟病 (CKD) 藥物市場的成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具還對全球慢性腎臟病 (ckd) 藥物市場的各個細分市場進行了包容性評估。慢性腎臟病 (ckd) 藥物產業的成長和趨勢為本研究提供了整體方法。

市場區隔

慢性腎臟病 (CKD) 藥物市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人口統計數據以及即將到來的機會。

按藥物類別

ACE抑制劑
血管張力素-II 受體阻斷劑
鈣通道阻斷劑
BETA受體阻斷劑
紅血球生成促效劑 (Esas)
利尿劑
其他

按最終用戶

醫院
專科診所

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲的慢性腎臟病 (CKD) 藥物市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。慢性腎臟病（CKD）藥物市場的主要參與者包括羅氏有限公司、輝瑞公司、賽諾菲公司、葛蘭素史克公司、Kissei Pharmaceutical Co. Ltd.、艾伯維公司、Akebia Therapeutics Inc.、阿斯特捷利康公司、安進公司(Amgen Inc.)、梯瓦製藥工業有限公司(Teva Pharmaceutical Industries Ltd.)。、財務概覽、合作、新產品開發、新產品發布、以及其他進度。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 8 章：慢性腎臟病 (CKD) 藥品公司的競爭格局

慢性腎臟病（CKD）藥物市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 9 章：公司簡介

頂級公司市佔率分析
市場集中度
F. Hoffmann-La Roche Ltd.

公司簡介
公司收入
產品
最近的發展

Pfizer Inc.

公司簡介
公司收入
產品
最近的發展

Sanofi

公司簡介
公司收入
產品
最近的發展

GSK Plc

公司簡介
公司收入
產品
最近的發展

Kissei Pharmaceutical Co. Ltd.

公司簡介
公司收入
產品
最近的發展

AbbVie Inc.

公司簡介
公司收入
產品
最近的發展

Akebia Therapeutics Inc.

公司簡介
公司收入
產品
最近的發展

AstraZeneca

公司簡介
公司收入
產品
最近的發展

Amgen Inc.

公司簡介
公司收入
產品
最近的發展

Teva Pharmaceutical Industries Ltd.

公司簡介
公司收入
產品
最近的發展

註 - 在公司概況中，財務詳細資料和最新進展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR112114354

The global demand for Chronic Kidney Disease (CKD) Drugs Market is presumed to reach the market size of nearly USD 23.69 Billion by 2032 from USD 15.06 Billion in 2023 with a CAGR of 5.16% under the study period 2024 - 2032.

Chronic kidney disease (CKD) drugs are pharmaceutical agents used to treat and manage long-term kidney damage and dysfunction. They aim to slow the progression of kidney disease, control symptoms, manage complications, and reduce the risk of cardiovascular events and mortality concerned with impaired kidney function. These drugs may include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), diuretics, erythropoiesis-stimulating agents (ESAs), phosphate binders, and vitamin D analogs, among others.

MARKET DYNAMICS

The spurring incidence of risk factors such as diabetes, hypertension, obesity, and aging populations drives the prevalence of CKD, leading to a growing patient population in need of pharmacological interventions to slow disease progression, manage symptoms, and enhance quality of life. With factors such as the increasing awareness of CKD, early detection initiatives, and the implementation of screening programs driving the identification of high-risk individuals and asymptomatic cases, there is a growing demand for CKD drugs that offer renoprotective effects, cardiovascular risk reduction, and symptom relief in patients with CKD stages 1 to 5. Additionally, advancements in renal biology, pathophysiology, and biomarker research enable the identification of novel drug targets, mechanisms of action, and therapeutic strategies for CKD treatment and management.

Moreover, the increasing recognition of CKD as a global public health challenge drives market innovation as pharmaceutical companies, biotech startups, and academic researchers invest in drug discovery and development programs targeting CKD complications. Furthermore, the evolving regulatory landscape, clinical trial design, and reimbursement policies drive market competition, pricing dynamics, and market access for CKD drugs as manufacturers navigate regulatory pathways, demonstrate clinical efficacy, and secure market approvals. However, concerns over drug safety, effectiveness, and adverse effects may challenge the chronic kidney disease (CKD) drugs market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of chronic kidney disease (ckd) drugs. The growth and trends of chronic kidney disease (ckd) drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the chronic kidney disease (ckd) drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

ACE Inhibitors
Angiotensin-Ii Receptor Blockers
Calcium Channel Blockers
Beta Blockers
Erythropoiesis-Stimulating Agents (Esas)
Diuretics
Others

By End-User

Hospitals
Specialty Clinics

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Chronic Kidney Disease (CKD) Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Chronic Kidney Disease (CKD) Drugs market include F. Hoffmann-La Roche Ltd., Pfizer Inc., Sanofi, GSK plc, Kissei Pharmaceutical Co. Ltd., AbbVie Inc., Akebia Therapeutics Inc., AstraZeneca, Amgen Inc., Teva Pharmaceutical Industries Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. CHRONIC KIDNEY DISEASE (CKD) DRUGS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By End-user
- 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL CHRONIC KIDNEY DISEASE (CKD) DRUGS MARKET ANALYSIS BY DRUG CLASS

5.1. Overview By Drug Class
5.2. Historical and Forecast Data
5.3. Analysis By Drug Class
5.4. ACE Inhibitors Historic and Forecast Sales By Regions
5.5. Angiotensin-II Receptor Blockers Historic and Forecast Sales By Regions
5.6. Calcium Channel Blockers Historic and Forecast Sales By Regions
5.7. Beta Blockers Historic and Forecast Sales By Regions
5.8. Erythropoiesis-stimulating Agents (ESAs) Historic and Forecast Sales By Regions
5.9. Diuretics Historic and Forecast Sales By Regions
5.10. Others Historic and Forecast Sales By Regions

6. GLOBAL CHRONIC KIDNEY DISEASE (CKD) DRUGS MARKET ANALYSIS BY END-USER

6.1. Overview By End-user
6.2. Historical and Forecast Data
6.3. Analysis By End-user
6.4. Hospitals Historic and Forecast Sales By Regions
6.5. Specialty Clinics Historic and Forecast Sales By Regions

7. GLOBAL CHRONIC KIDNEY DISEASE (CKD) DRUGS MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1 Overview, Historic and Forecast Data Sales Analysis
- 7.3.2 North America By Segment Sales Analysis
- 7.3.3 North America By Country Sales Analysis
- 7.3.4 United States Sales Analysis
- 7.3.5 Canada Sales Analysis
- 7.3.6 Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1 Overview, Historic and Forecast Data Sales Analysis
- 7.4.2 Europe By Segment Sales Analysis
- 7.4.3 Europe By Country Sales Analysis
- 7.4.4 United Kingdom Sales Analysis
- 7.4.5 France Sales Analysis
- 7.4.6 Germany Sales Analysis
- 7.4.7 Italy Sales Analysis
- 7.4.8 Russia Sales Analysis
- 7.4.9 Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1 Overview, Historic and Forecast Data Sales Analysis
- 7.5.2 Asia Pacific By Segment Sales Analysis
- 7.5.3 Asia Pacific By Country Sales Analysis
- 7.5.4 China Sales Analysis
- 7.5.5 India Sales Analysis
- 7.5.6 Japan Sales Analysis
- 7.5.7 South Korea Sales Analysis
- 7.5.8 Australia Sales Analysis
- 7.5.9 South East Asia Sales Analysis
- 7.5.10 Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1 Overview, Historic and Forecast Data Sales Analysis
- 7.6.2 Latin America By Segment Sales Analysis
- 7.6.3 Latin America By Country Sales Analysis
- 7.6.4 Brazil Sales Analysis
- 7.6.5 Argentina Sales Analysis
- 7.6.6 Peru Sales Analysis
- 7.6.7 Chile Sales Analysis
- 7.6.8 Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1 Overview, Historic and Forecast Data Sales Analysis
- 7.7.2 Middle East & Africa By Segment Sales Analysis
- 7.7.3 Middle East & Africa By Country Sales Analysis
- 7.7.4 Saudi Arabia Sales Analysis
- 7.7.5 UAE Sales Analysis
- 7.7.6 Israel Sales Analysis
- 7.7.7 South Africa Sales Analysis
- 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE CHRONIC KIDNEY DISEASE (CKD) DRUGS COMPANIES

8.1. Chronic Kidney Disease (CKD) Drugs Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9. COMPANY PROFILES OF CHRONIC KIDNEY DISEASE (CKD) DRUGS INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. F. Hoffmann-La Roche Ltd.
- 9.3.1 Company Overview
- 9.3.2 Company Revenue
- 9.3.3 Products
- 9.3.4 Recent Developments
9.4. Pfizer Inc.
- 9.4.1 Company Overview
- 9.4.2 Company Revenue
- 9.4.3 Products
- 9.4.4 Recent Developments
9.5. Sanofi
- 9.5.1 Company Overview
- 9.5.2 Company Revenue
- 9.5.3 Products
- 9.5.4 Recent Developments
9.6. GSK Plc
- 9.6.1 Company Overview
- 9.6.2 Company Revenue
- 9.6.3 Products
- 9.6.4 Recent Developments
9.7. Kissei Pharmaceutical Co. Ltd.
- 9.7.1 Company Overview
- 9.7.2 Company Revenue
- 9.7.3 Products
- 9.7.4 Recent Developments
9.8. AbbVie Inc.
- 9.8.1 Company Overview
- 9.8.2 Company Revenue
- 9.8.3 Products
- 9.8.4 Recent Developments
9.9. Akebia Therapeutics Inc.
- 9.9.1 Company Overview
- 9.9.2 Company Revenue
- 9.9.3 Products
- 9.9.4 Recent Developments
9.10. AstraZeneca
- 9.10.1 Company Overview
- 9.10.2 Company Revenue
- 9.10.3 Products
- 9.10.4 Recent Developments
9.11. Amgen Inc.
- 9.11.1 Company Overview
- 9.11.2 Company Revenue
- 9.11.3 Products
- 9.11.4 Recent Developments
9.12. Teva Pharmaceutical Industries Ltd.
- 9.12.1 Company Overview
- 9.12.2 Company Revenue
- 9.12.3 Products
- 9.12.4 Recent Developments